These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1908119)

  • 1. Recombinant factor VIII: an introduction.
    Büchel KH
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):1-4. PubMed ID: 1908119
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant factor VIII: are we really getting more for less?
    Gorlin JB; Ewenstein BM
    J Pediatr; 1997 Apr; 130(4):507-9. PubMed ID: 9108841
    [No Abstract]   [Full Text] [Related]  

  • 3. The current status of recombinant human factor VIII.
    Aronson DL
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):55-6. PubMed ID: 1908131
    [No Abstract]   [Full Text] [Related]  

  • 4. [Recombinant factor VIII concentrate].
    Fukutake K
    Rinsho Byori; 1992 Mar; Suppl 92():94-106. PubMed ID: 1583781
    [No Abstract]   [Full Text] [Related]  

  • 5. Design of clinical studies with recombinant factor VIII. The rFactor VIII Clinical Trial Group.
    Pennington JE; Schwartz RS
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):27-8. PubMed ID: 1908123
    [No Abstract]   [Full Text] [Related]  

  • 6. [Recombinant factor VIII].
    Tusell JM
    Sangre (Barc); 1993 Apr; 38(2):139-42. PubMed ID: 8516727
    [No Abstract]   [Full Text] [Related]  

  • 7. Modern treatment of hemophilia: from the shadows towards the light.
    Mannucci PM
    Thromb Haemost; 1993 Jul; 70(1):17-23. PubMed ID: 8236096
    [No Abstract]   [Full Text] [Related]  

  • 8. Hemophilia.
    Aledort LM
    N Engl J Med; 2001 Oct; 345(14):1066; author reply 1067. PubMed ID: 11586968
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia.
    White GC; McMillan CW; Kingdon HS; Shoemaker CB
    N Engl J Med; 1989 Jan; 320(3):166-70. PubMed ID: 2492083
    [No Abstract]   [Full Text] [Related]  

  • 10. The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies.
    Engelfriet CP; Reesink HW; Mannucci PM; Gringeri A; Ingerslev J; Brettler DB; Mauser-Bunschoten EP; Negrier C; Berntorp E; Smith OP; Shapiro AD
    Vox Sang; 2000; 78(4):256-61. PubMed ID: 10970234
    [No Abstract]   [Full Text] [Related]  

  • 11. The need for recombinant factor VIII: historical background and rationale.
    Hilgartner MW
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):6-9. PubMed ID: 1908132
    [No Abstract]   [Full Text] [Related]  

  • 12. Factor VIII inhibitors.
    Gilles JG; Jacquemin MG; Saint-Remy JM
    Thromb Haemost; 1997 Jul; 78(1):641-6. PubMed ID: 9198231
    [No Abstract]   [Full Text] [Related]  

  • 13. Recombinant factor VIII in hemophilia A: the Canadian experience.
    Blanchette VS
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant factor VIII in hemophilia.
    Cohen A; Butler R
    N Engl J Med; 1991 May; 324(21):1515-6. PubMed ID: 1902552
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of single factor deficiencies: a case study approach.
    Marques MB
    Clin Lab Sci; 2003; 16(2):120-2. PubMed ID: 12757193
    [No Abstract]   [Full Text] [Related]  

  • 16. Factor VIII inhibitor and severity of hemophilia.
    Schoppmann A; Waytes AT
    Thromb Haemost; 1996 Aug; 76(2):280-1. PubMed ID: 8865549
    [No Abstract]   [Full Text] [Related]  

  • 17. [Molecular biology of human factor VIII and its production by gene engineering technique].
    Sugiyama T; Tajima Y
    Tanpakushitsu Kakusan Koso; 1990 Oct; 35(14):2671-87. PubMed ID: 2125133
    [No Abstract]   [Full Text] [Related]  

  • 18. Development and introduction of recombinant factor VIII--a clinician's experience.
    Lusher JM
    Haemophilia; 2012 Jul; 18(4):483-6. PubMed ID: 22512315
    [No Abstract]   [Full Text] [Related]  

  • 19. Recombinant factor VIII concentrate. The MSAC, Canadian Hemophilia Society. Canadian Hemophilia Clinic Directors Group.
    Walker I; Poon MC
    Lancet; 1992 Jan; 339(8784):61-2. PubMed ID: 1345984
    [No Abstract]   [Full Text] [Related]  

  • 20. [Percutaneous nephrolithotripsy supported by recombinant factor VIII in a patient with hemophilia A, a Jehovah's Witness].
    Azuno Y; Kaku K
    Rinsho Ketsueki; 1995 Dec; 36(12):1337-41. PubMed ID: 8587168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.